Uganda’s QCI to invest $80m in AIDS and anti-malarial drug capacity

Related tags Finance Hiv

Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.

The investment, which will take place over the next two years according to a Bloomberg​ report, will begin with a $30m expansion of its facility in the capital Kampala with funding provided by shareholders and the sale of new stock.

The second phase of the project, which will also be funded by shareholders, will see the addition of a brand new line for the production of pharmaceutical ingredients according to QCI marketing manager George Baguma who spoke with the newsier.

One of QCI’s biggest shareholders is Indian drugmaker Cipla, for which the Ugandan firm produces the combination antiretroviral drug Duovir-N.

Related news

Show more

Related product

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.